RxDoctor Payments Data

Zahid Shaikh, MD

Internal Medicine · Walnut Creek, CANPI 1740441294

Payments from drug & device makers

$594in general payments, 2019–2025

Across 6 payments — averaging $98.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$226
  • AbbVie$218
  • AstraZeneca$121
  • Pfizer$28

What the payments were for

  • Food & beverage$594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson2$226
AbbVie(2 entities)2$218
AstraZeneca1$121
Pfizer1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$594 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$846,479
Medicare patients
961
Services billed
8,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban601$186,546
XifaxanRifaximin32$46,135
XareltoRivaroxaban162$40,785
JardianceEmpagliflozin112$38,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$24,254
ProcritEpoetin Alfa20$17,558
TrulicityDulaglutide29$17,525
Lansoprazole72$15,259
NuedextaDextromethorphan Hbr/Quinidine15$13,744
Gabapentin576$13,017
Atorvastatin Calcium1,028$12,513
ArexvyRsvpref3 Antigen/As01e/Pf41$12,499
OzempicSemaglutide12$12,354
EntrestoSacubitril/Valsartan27$11,519
Levetiracetam274$10,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$186,546601 claims
Johnson & JohnsonXarelto, Procrit$226$58,344182 claims
AstraZenecaBrilinta$121$8,55139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →